Correction to “B‐cell Maturation Antigen‐Based Therapies Post‐Talquetamab in Relapsed or Refractory Multiple Myeloma”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMultiple Myeloma Research and Treatments · Protein Degradation and Inhibitors · Synthesis and Biological Evaluation
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, et al. B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma. eJHaem. 2024;5:554‐59. doi:10.1002/jha2.896
Carolina Schinke has mistakenly not declared her Conflict of Interest and would like to add a sentence stating “CS has participated in Advisory Board Meetings of Janssen, Pfizer and Arcellx”.
We apologize for this error.